Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 709

1.

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors.

Janning M, Kobus F, Babayan A, Wikman H, Velthaus JL, Bergmann S, Schatz S, Falk M, Berger LA, Böttcher LM, Päsler S, Gorges TM, O'Flaherty L, Hille C, Joosse SA, Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K, Loges S.

Cancers (Basel). 2019 Jun 17;11(6). pii: E835. doi: 10.3390/cancers11060835.

2.

Fatal Myelotoxicity Following Palliative Chemotherapy With Cisplatin and Gemcitabine in a Patient With Stage IV Cholangiocarcinoma Linked to Post Mortem Diagnosis of Fanconi Anemia.

Engel NW, Schliffke S, Schüller U, Frenzel C, Bokemeyer C, Kubisch C, Lessel D.

Front Oncol. 2019 May 22;9:420. doi: 10.3389/fonc.2019.00420. eCollection 2019.

3.

Impact of taste and smell training on taste disorders during chemotherapy - TASTE trial.

von Grundherr J, Koch B, Grimm D, Salchow J, Valentini L, Hummel T, Bokemeyer C, Stein A, Mann J.

Cancer Manag Res. 2019 May 16;11:4493-4504. doi: 10.2147/CMAR.S188903. eCollection 2019.

4.

Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib.

Janjetovic S, Asemissen AM, Dicker F, Binder M, Dierlamm J, Bokemeyer C, Schafhausen P.

Tumori. 2019 Apr 1:300891619839473. doi: 10.1177/0300891619839473. [Epub ahead of print]

PMID:
30935343
5.

Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors-past, present, and future considerations.

Oing C, Skowron MA, Bokemeyer C, Nettersheim D.

Andrology. 2019 Mar 29. doi: 10.1111/andr.12611. [Epub ahead of print] Review.

PMID:
30924611
6.

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.

Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzelbecker J, Heidenreich A, Cremers JF, Oing C, Hermanns T, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G.

J Clin Oncol. 2019 Jun 1;37(16):1412-1423. doi: 10.1200/JCO.18.01480. Epub 2019 Mar 15.

PMID:
30875280
7.

Current pharmacotherapy for testicular germ cell cancer.

Alsdorf W, Seidel C, Bokemeyer C, Oing C.

Expert Opin Pharmacother. 2019 May;20(7):837-850. doi: 10.1080/14656566.2019.1583745. Epub 2019 Mar 8. Review.

PMID:
30849243
8.

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.

Ludwig H, Bokemeyer C, Aapro M, Boccadoro M, Gascón P, Denhaerynck K, Krendyukov A, Abraham I, MacDonald K.

Future Oncol. 2019 Mar;15(8):897-907. doi: 10.2217/fon-2018-0814. Epub 2019 Mar 4.

9.

Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.

Tintelnot J, Baum N, Schultheiß C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schuetze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M.

Mol Cancer Ther. 2019 Apr;18(4):823-833. doi: 10.1158/1535-7163.MCT-18-0849. Epub 2019 Mar 1.

PMID:
30824613
10.

Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.

Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G, Loges S.

Int J Cancer. 2019 Aug 1;145(3):857-868. doi: 10.1002/ijc.32163. Epub 2019 Mar 4.

PMID:
30694523
11.

5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells.

Oing C, Verem I, Mansour WY, Bokemeyer C, Dyshlovoy S, Honecker F.

Int J Mol Sci. 2018 Dec 21;20(1). pii: E21. doi: 10.3390/ijms20010021.

12.

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE.

Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7.

PMID:
30529901
13.

Apixaban for the Treatment of Chronic Disseminated Intravascular Coagulation: A Report of Two Cases.

Janjetovic S, Holstein K, Dicke C, Bokemeyer C, Langer F.

Hamostaseologie. 2018 Nov 19. doi: 10.1055/s-0038-1675386. [Epub ahead of print]

PMID:
30453340
14.

Palliative treatment of germ cell cancer.

Oing C, Giannatempo P, Honecker F, Oechsle K, Bokemeyer C, Beyer J.

Cancer Treat Rev. 2018 Dec;71:102-107. doi: 10.1016/j.ctrv.2018.10.007. Epub 2018 Oct 22. Review.

15.

Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients.

Samsen A, von der Heyde S, Bokemeyer C, David KA, Flath B, Graap M, Grebenstein B, Heflik L, Hollburg W, Layer P, von Leitner E, Overkamp F, Saeger W, Schneider S, von Seydewitz CU, Stang A, Stein A, Zornig C, Juhl H.

Oncotarget. 2018 Oct 5;9(78):34794-34809. doi: 10.18632/oncotarget.26198. eCollection 2018 Oct 5.

16.

[Positron emission tomography in germ cell tumors in men : Possibilities and limitations].

Schriefer P, Hartmann M, Oechsle K, Meyer CP, Klutmann S, Fisch M, Bokemeyer C, Oing C.

Urologe A. 2019 Apr;58(4):418-423. doi: 10.1007/s00120-018-0797-x. Review. German.

PMID:
30374517
17.

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.

Ludwig H, Gascón P, Bokemeyer C, Aapro M, Boccadoro M, Denhaerynck K, Krendyukov A, MacDonald K, Abraham I.

Support Care Cancer. 2019 Jun;27(6):2301-2312. doi: 10.1007/s00520-018-4513-6. Epub 2018 Oct 20.

PMID:
30343410
18.

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv271. doi: 10.1093/annonc/mdy323. No abstract available.

PMID:
30285221
19.

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.

Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Díaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL.

Eur J Cancer. 2018 Nov;103:205-213. doi: 10.1016/j.ejca.2018.08.020. Epub 2018 Sep 27.

PMID:
30268921
20.

The Impact of Bleeding Disorders on the Socioeconomic Status of Adult Patients.

Holstein K, von Mackensen S, Bokemeyer C, Langer F.

Hamostaseologie. 2018 Aug;38(3):150-157. doi: 10.5482/HAMO-16-12-0047. Epub 2018 Sep 27.

PMID:
30261520
21.

Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.

Fenner M, Oing C, Dieing A, Gauler T, Oechsle K, Lorch A, Hentrich M, Kopp HG, Bokemeyer C, Honecker F.

J Cancer Res Clin Oncol. 2019 Mar;145(3):717-723. doi: 10.1007/s00432-018-2752-z. Epub 2018 Sep 19.

PMID:
30232558
22.

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.

Berger LA, Janning M, Velthaus JL, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S.

J Thorac Oncol. 2018 Dec;13(12):e243-e246. doi: 10.1016/j.jtho.2018.08.2025. Epub 2018 Sep 8. No abstract available.

PMID:
30205165
23.

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A.

Ann Oncol. 2018 Aug 1;29(8):1658-1686. doi: 10.1093/annonc/mdy217.

PMID:
30113631
24.

Der ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis.

Bokemeyer C, Busse R, Engel J, Gebauer A, Hallek M, Heinemann V, Lüftner D, Wörmann B.

Oncol Res Treat. 2018;41 Suppl 3:2-26. doi: 10.1159/000490082. Epub 2018 Jul 26. No abstract available.

25.

Vorwort.

Hallek M, Bokemeyer C, Lüftner D, Weissinger F.

Oncol Res Treat. 2018;41 Suppl 3:1. doi: 10.1159/000491683. Epub 2018 Jul 26. No abstract available.

26.

A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells.

Brandt A, Matschke J, Fehrle W, von Wenserski L, Bokemeyer C, Illerhaus G, Binder M.

Leuk Lymphoma. 2019 Feb;60(2):334-340. doi: 10.1080/10428194.2018.1482538. Epub 2018 Jul 22.

PMID:
30033830
27.

Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer.

Oing C, Bokemeyer C.

Curr Opin Urol. 2018 Sep;28(5):479-484. doi: 10.1097/MOU.0000000000000531. Review.

PMID:
29957683
28.

Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.

Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Dos Santos C, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W.

Oncogene. 2018 Sep;37(39):5269-5280. doi: 10.1038/s41388-018-0288-y. Epub 2018 May 31.

29.

Synthesis and anticancer activity of the derivatives of marine compound rhizochalin in castration resistant prostate cancer.

Dyshlovoy SA, Otte K, Tabakmakher KM, Hauschild J, Makarieva TN, Shubina LK, Fedorov SN, Bokemeyer C, Stonik VA, von Amsberg G.

Oncotarget. 2018 Mar 30;9(24):16962-16973. doi: 10.18632/oncotarget.24764. eCollection 2018 Mar 30.

30.

Blockade of Myeloid-Derived Suppressor Cell Expansion with All-Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy.

Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos IM, Taverna F, Kuhlencord M, Gensch V, Päsler S, Vinckier S, Brandner JM, Pantel K, Bokemeyer C, Vogl T, Roth J, Carmeliet P, Loges S.

Cancer Res. 2018 Jun 15;78(12):3220-3232. doi: 10.1158/0008-5472.CAN-17-3415. Epub 2018 Apr 19.

31.

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.

Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M.

Oncoimmunology. 2018 Jan 15;7(4):e1417720. doi: 10.1080/2162402X.2017.1417720. eCollection 2018.

32.

Evaluation of a program for routine implementation of shared decision-making in cancer care: study protocol of a stepped wedge cluster randomized trial.

Scholl I, Hahlweg P, Lindig A, Bokemeyer C, Coym A, Hanken H, Müller V, Smeets R, Witzel I, Kriston L, Härter M.

Implement Sci. 2018 Mar 27;13(1):51. doi: 10.1186/s13012-018-0740-y.

33.

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells.

Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L, Ben Batalla I, Gensch V, Päsler S, Wu L, Wanior M, Taipaleenmäki H, Bolamperti S, Najafova Z, Pantel K, Bokemeyer C, Qi J, Hesse E, Knapp S, Johnsen S, Loges S.

Haematologica. 2018 Jun;103(6):939-948. doi: 10.3324/haematol.2017.181354. Epub 2018 Mar 22.

34.

BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.

Oing C, Tennstedt P, Simon R, Volquardsen J, Borgmann K, Bokemeyer C, Petersen C, Dikomey E, Rothkamm K, Mansour WY.

Cancer Lett. 2018 Jun 1;423:60-70. doi: 10.1016/j.canlet.2018.03.007. Epub 2018 Mar 8.

PMID:
29526801
35.

Therapeutic approaches for refractory germ cell cancer.

Oing C, Seidel C, Bokemeyer C.

Expert Rev Anticancer Ther. 2018 Apr;18(4):389-397. doi: 10.1080/14737140.2018.1450630. Epub 2018 Mar 12. Review.

PMID:
29516750
36.

Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.

Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Bokemeyer C.

Eur J Cancer. 2018 May;94:16-25. doi: 10.1016/j.ejca.2018.01.113. Epub 2018 Mar 20.

PMID:
29505967
37.

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv96-iv110. doi: 10.1093/annonc/mdx758. No abstract available.

38.

Treatment of Metastatic Spindle Epithelial Tumor with Thymus-Like Differentiation (SETTLE) - Long-Term Disease Control by Multimodal Therapy.

Quidde J, Alsdorf WH, von Amsberg G, Wilczak W, Bokemeyer C.

Oncol Res Treat. 2018;41(1-2):58-60. doi: 10.1159/000480017. Epub 2018 Jan 22. Erratum in: Oncol Res Treat. 2018;41(3):146.

39.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD).

J Natl Cancer Inst. 2018 Jun 1;110(6):638-648. doi: 10.1093/jnci/djx253.

40.

Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel.

Boormans JL, Mayor de Castro J, Marconi L, Yuan Y, Laguna Pes MP, Bokemeyer C, Nicolai N, Algaba F, Oldenburg J, Albers P.

Eur Urol. 2017 Nov 20. pii: S0302-2838(17)30826-6. doi: 10.1016/j.eururo.2017.09.025. [Epub ahead of print] Review.

PMID:
29100813
41.

Specific Characteristics of Patients with Advanced Genitourinary Cancer Receiving Specialized Inpatient Palliative Care.

Iversen K, Oechsle K, Oing C, Bokemeyer C, Seidel C.

Oncol Res Treat. 2017;40(10):609-614. doi: 10.1159/000478934. Epub 2017 Sep 19.

42.

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B.

Wroblewski M, Bauer R, Cubas Córdova M, Udonta F, Ben-Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J, Schulze C, Pantel K, Bokemeyer C, Loges S.

Nat Commun. 2017 Aug 16;8(1):269. doi: 10.1038/s41467-017-00327-8.

43.

The impact of bleeding disorders on the socioeconomic status of adult patients. Results of a comparative single centre cohort study.

Holstein K, von Mackensen S, Bokemeyer C, Langer F.

Hamostaseologie. 2017 Jul 10;99(99). doi: 10.5482/HAMO-16-12-0047. [Epub ahead of print]

PMID:
28692112
44.

[New Aspects in Treatment of Metastatic Prostate Cancer].

von Amsberg G, Bokemeyer C.

Dtsch Med Wochenschr. 2017 Aug;142(15):1106-1110. doi: 10.1055/s-0043-105768. Epub 2017 Jun 23. German.

PMID:
28645133
45.

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.

Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, Binder M.

Haematologica. 2017 Sep;102(9):e368-e370. doi: 10.3324/haematol.2017.169235. Epub 2017 May 18. No abstract available.

46.

Testis cancer: some problems still remain unsolved.

Albers P, Bokemeyer C.

World J Urol. 2017 Aug;35(8):1159-1160. doi: 10.1007/s00345-017-2041-5. Epub 2017 May 16. No abstract available.

PMID:
28509970
47.

Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells.

Dyshlovoy SA, Rast S, Hauschild J, Otte K, Alsdorf WH, Madanchi R, Kalinin VI, Silchenko AS, Avilov SA, Dierlamm J, Honecker F, Stonik VA, Bokemeyer C, von Amsberg G.

Leuk Lymphoma. 2017 Dec;58(12):2905-2915. doi: 10.1080/10428194.2017.1317091. Epub 2017 May 16.

PMID:
28508718
48.

Quality of life, psychological burden, needs, and satisfaction during specialized inpatient palliative care in family caregivers of advanced cancer patients.

Ullrich A, Ascherfeld L, Marx G, Bokemeyer C, Bergelt C, Oechsle K.

BMC Palliat Care. 2017 May 10;16(1):31. doi: 10.1186/s12904-017-0206-z.

49.

Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension.

Harbaum L, Baaske KM, Simon M, Oqueka T, Sinning C, Glatzel A, Lüneburg N, Sydow K, Bokemeyer C, Klose H.

BMC Pulm Med. 2017 Apr 26;17(1):72. doi: 10.1186/s12890-017-0407-5.

50.

Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin.

Dyshlovoy SA, Otte K, Venz S, Hauschild J, Junker H, Makarieva TN, Balabanov S, Alsdorf WH, Madanchi R, Honecker F, Bokemeyer C, Stonik VA, von Amsberg G.

Proteomics. 2017 Jun;17(11). doi: 10.1002/pmic.201700048.

PMID:
28445005

Supplemental Content

Loading ...
Support Center